Genmab — December 2022
-
2 Cancer Meds in PIII, Genmab to Rev Up Rep Hiring to Build Sales Regime in Japan - Danish antibody specialist Genmab will hire sales reps in Japan to establish an independent marketing organization as it preps for the anticipated launch of two cancer drugs now in late-stage development in the country, local president Mika Takaki said https://pj.jiho.jp/article/247899
-
Genmabs teknologiplatforme står foran gennembrud
David Mygind
Fredag 02. december 2022 - https://ugebrev.dk/flashnews/genmabs-teknologiplatforme-staar-foran-gennembrud/ -
-
Analysen fra Mygind
er spritny (30-11-2022) og kursmål hæves til 3400 anbefaling neutral. -
Jo, på sidste side er der et afsnit der omhandler nyt kursmål.
-
OK, jeg har har selve analysen her. Så der må være sket en fejl.
-
På hjemmesiden står der at de 3150 er et 6 måneders kursmål. Er de 3400 i selve analysen også for 6 måneder eller står der ikke noget om den del?
-
Sanofi falder efter kommentar om kontantbud på Horizon https://www.proinvestor.com/investornyt/911266/sanofi-falder-efter-kommentar-om-kontantbud-pa-horizon
-
De 3400 er i selve analysen
-
12 måneders kursmål
-
Jeg tror de har lavet en fejl
-
Tak GB.
-
Gode jobtal og markedet falder…
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind